EQS News: Marinomed Biotech AG with new sales production partners and EU patent for Carragelose

adminn

12 months ago

EQS News: Marinomed Biotech AG with new sales production partners and EU patent for Carragelose

EQS News: Marinomed Biotech AG / Key word(s): Contract/patent Marinomed Biotech AG with new sales and production partners as well as EU patent for Carragelose 12/14/2023 / 07:45 CET/CEST The issuer is responsible for the content of the announcement / Editor responsible. ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ══════════════ Marinomed Biotech AG with new sales and production partners as well as EU patent for Carragelose • Marinomed starts new sales partnership with Favorex Ptd Ltd, a subsidiary of DKSH, for the distribution of a Carragelose nasal spray in Southeast Asia • EU Patent Office issued approval decision to protect the use of carrageenan for the prophylactic and therapeutic treatment of SARS-CoV-2 infections • New sales partner for the production of Carragelose lozenges, expansion of the sales network planned Korneuburg, Austria, December 14, 2023 – Marinomed Biotech AG (VSE:MARI) signed a license agreement with Favorex Ptd Ltd, a subsidiary of DKSH and part of the Healthcare division, to market a Carragelose nasal spray in Malaysia, Myanmar, Thailand and the Philippines. DKSH is a leading provider of market expansion services with almost 160 years of experience, operating in 37 markets worldwide. With a tailored, comprehensive service portfolio, DKSH Healthcare is a trusted partner for healthcare solutions across Asia and beyond. In addition, the European Patent Office granted a patent covering the use of carrageenan in the prophylactic and therapeutic treatment of SARS-CoV-2 infections. This patent is one of many protecting the use of virus-blocking carrageenan against a range of respiratory viruses. In addition, Marinomed was able to successfully start producing Carragelose lozenges with its new Turkish production partner Meksmar. Marinomed has already supplied its first customers with products and plans to further expand sales of Carragelose lozenges in the future. “We have already had a lot of good news for our Carragelose business in 2023, including the launch of the allergen-blocking nasal spray and lubricating eye drops. Closing the year with a new partnership, a European patent and a successful manufacturing process shows once again that Carragelose is a success story,” says Andreas Grassauer, CEO of Marinomed. “By launching new products and expanding our sales network through new partnerships, we are following our strategy to continually increase the value of this asset. We look forward to exploiting the full potential of the Carragelose platform.” About Favorex Pte Ltd and DKSH Favorex is a subsidiary of the DKSH Group and part of the Healthcare Business Unit. Favorex focuses on licensing and marketing healthcare products for patients and healthcare professionals, leveraging DKSH’s extensive expertise and network in the Asia Pacific region. The goal of DKSH is to enrich people’s lives. For more than 150 years, the company has been growing companies in Asia and beyond through its Healthcare, Consumer Goods, Performance Materials and Technology divisions. As a leading provider of market expansion services, DKSH offers procurement, market analysis, marketing and sales, eCommerce, distribution and logistics as well as other customer services. DKSH is a member of the United Nations Global Compact and adheres to its principles-based approach to responsible behavior. DKSH is listed on the SIX Swiss Exchange and operates in 37 markets with 32,600 specialists, generating net sales of CHF 11.3 billion in 2022. The DKSH Business Unit Healthcare is a reliable partner for healthcare solutions in Asia and beyond. With around 7,990 specialists, the business unit generated net sales of CHF 5.6 billion in 2022. (1) www.dksh.com/hec

About Meksmar Meksmar was founded in 1996 and specializes in the production of lozenges, herbal lozenges and cough drops. Meksmar is the leading manufacturer of pharmaceutical grade lozenges and has 16 registered brands and has contract manufactured more than 50 brands for domestic and international pharmaceutical companies. Meksmar exports its product range to 40 countries on 5 continents. Meksmar offers a range of lozenges and lozenges that offer unique benefits for sore throats, colds and hoarseness. Meksmar also offers unique recipes with vitamins, minerals and natural extracts that give the body more strength. Production is carried out according to the standards of ISO 22000:2018, ISO 9001:2015, ISO 13485:2016 and GMP. About Carragelose®: Carragelose® is a sulfated polymer from red algae with a unique, broad spectrum of virus-blocking activity. It is known to be a tolerated, effective and safe agent for the prevention and treatment of viral respiratory diseases. Several clinical and preclinical studies have shown that Carragelose® forms a protective layer on the mucous membrane that prevents viruses from infecting cells. Laboratory studies and clinical data have confirmed that Carragelose® can also prevent the transmission of SARS-CoV-2.(2)^(1)^,(3)(2) Marinomed holds the patent rights to Carragelose® and has Carragelose® for distribution in Europe, North America, Australia and other countries in Asia and Latin America. Marinomed’s Carragelose® portfolio of nasal sprays and throat products can be found at (4) https://www.carragelose.com/en/portfolio/launched-productsthe scientific publications on Carragelose® at (5) https://www.marinomed.com/de/publikationen/wissenschaftliche-publikationen.

About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotechnology company with a growing development pipeline and globally marketed therapeutics. The company develops patent-protected, innovative products in the therapeutic areas of immunology and virology based on its Marinosolv® platform and the virus-blocking effect of Carragelose®. The Marinosolv® technology increases the solubility and bioavailability of poorly soluble active ingredients and is used to develop new therapeutics for indications in the area of autoreactive immune diseases. The Virology segment includes Carragelose®-based over-the-counter products for the prophylaxis and treatment of viral upper respiratory tract infections, partnered in more than 40 countries. The company is based in Korneuburg, Austria and is listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). Further information: (6) https://www.marinomed.com.

Inquiry note: Marinomed Biotech AG International media inquiries PR: Lucia Ziegler Metrum Communications: Roland Mayrl T: +43 2262 90300 158 T: +43 664 6126228 E-mail: (7)pr@marinomed.com E-mail: (9)marinomed@metrum.at IR: Stephanie Kniep T: +43 2262 90300 226 E-mail: (8)ir@marinomed.com Disclaimer This press release contains forward-looking statements based on current views, expectations and forecasts of the management of Marinomed Biotech AG about future events based. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described or otherwise expressed or implied by such statements. The current views, expectations and forecasts of the management of Marinomed Biotech AG are influenced by the context of such statements or words as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and Recognize “target”. Forward-looking statements speak only as of the date on which they are made. Marinomed Biotech AG undertakes no obligation to update, revise or revise any forward-looking statements contained in this press release, whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are brands of Marinomed AG. The brands are the property of Marinomed Biotech AG or are licensed out to partners in selected countries. (10)^(1) (11)https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article- IJGM (12)^(2) (13)https://www.marinomed.com/de/news/marinomed-biotech-ag-informs-about-positive-clinical-results-for-iota-carrageenan-nasal-spray-for -covid-19-praevention-1 ═════════════════════════════════════ ═════ ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ══════════════════════ 12/14/2023 CET/CEST Publication of a corporate news/financial announcement, transmitted by EQS Group AG. www.eqs.com